ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraakEnglish 
    • EnglishEnglish
    • norsknorsk
  • Administration/UB
View Item 
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for samfunnsmedisin
  • Artikler, rapporter og annet (samfunnsmedisin)
  • View Item
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for samfunnsmedisin
  • Artikler, rapporter og annet (samfunnsmedisin)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Systemic inflammation markers and cancer incidence in the UK Biobank

Permanent link
https://hdl.handle.net/10037/23575
DOI
https://doi.org/10.1007/s10654-021-00752-6
Thumbnail
View/Open
article.pdf (552.6Kb)
Published version (PDF)
Date
2021-05-25
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Author
Nøst, Therese Haugdahl; Alcala, Karine; Urbarova, Ilona; Byrne, Karl Smith; Guida, Florence; Sandanger, Torkjel M; Johansson, Mattias
Abstract
Systemic inflammation markers have been linked to increased cancer risk and mortality in a number of studies. However, few studies have estimated pre-diagnostic associations of systemic inflammation markers and cancer risk. Such markers could serve as biomarkers of cancer risk and aid in earlier identification of the disease. This study estimated associations between pre-diagnostic systemic inflammation markers and cancer risk in the prospective UK Biobank cohort of approximately 440,000 participants recruited between 2006 and 2010. We assessed associations between four immune-related markers based on blood cell counts: systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and risk for 17 cancer sites by estimating hazard ratios (HR) using flexible parametric survival models. We observed positive associations with risk for seven out of 17 cancers with SII, NLR, PLR, and negative associations with LMR. The strongest associations were observed for SII for colorectal and lung cancer risk, with associations increasing in magnitude for cases diagnosed within one year of recruitment. For instance, the HR for colorectal cancer per standard deviation increment in SII was estimated at 1.09 (95% CI 1.02–1.16) in blood drawn five years prior to diagnosis and 1.50 (95% CI 1.24–1.80) in blood drawn one month prior to diagnosis. We observed associations between systemic inflammation markers and risk for several cancers. The increase in risk the last year prior to diagnosis may reflect a systemic immune response to an already present, yet clinically undetected cancer. Blood cell ratios could serve as biomarkers of cancer incidence risk with potential for early identification of disease in the last year prior to clinical diagnosis.
Publisher
Springer
Citation
Nøst TH, Alcala, Urbarova, Byrne, Guida, Sandanger, Johansson. Systemic inflammation markers and cancer incidence in the UK Biobank. European Journal of Epidemiology (EJE). 2021
Metadata
Show full item record
Collections
  • Artikler, rapporter og annet (samfunnsmedisin) [1515]
Copyright 2021 The Author(s)

Browse

Browse all of MuninCommunities & CollectionsAuthor listTitlesBy Issue DateBrowse this CollectionAuthor listTitlesBy Issue Date
Login

Statistics

View Usage Statistics
UiT

Munin is powered by DSpace

UiT The Arctic University of Norway
The University Library
uit.no/ub - munin@ub.uit.no

Accessibility statement (Norwegian only)